Clinical Trials Browser

High Grade Serous Carcinoma

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase 2 Active not recruiting

273 enrolled 22 charts

Breast

Triple Negative Breast Neoplasms

NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms

NCT05941897 2026-03-05

LOTOS

Phase 2 Active not recruiting

39 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Clinical Trials

CAPRI

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

LOTOS

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Olaparib With Ceralasertib in Recurrent Osteosarcoma

ATARI

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

AUSTRAL

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

HUDSON

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

ATRiBRAVE

PHOENIX

MONETTE

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

PIONeeR

AZD6738 Plus Durvalumab in Biliary Tract Cancer

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

OLAPCO

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

DUETTE

Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

plasmaMATCH